BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33741417)

  • 1. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems.
    Mirzaei S; Mahabady MK; Zabolian A; Abbaspour A; Fallahzadeh P; Noori M; Hashemi F; Hushmandi K; Daneshi S; Kumar AP; Aref AR; Samarghandian S; Makvandi P; Khan H; Hamblin MR; Ashrafizadeh M; Zarrabi A
    Life Sci; 2021 Jun; 275():119368. PubMed ID: 33741417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
    Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
    J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities.
    Ahirwar K; Kumar A; Srivastava N; Saraf SA; Shukla R
    Int J Biol Macromol; 2024 May; 266(Pt 1):131048. PubMed ID: 38522697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin.
    Wang K; Park JO; Zhang M
    J Gene Med; 2013 Jan; 15(1):42-50. PubMed ID: 23319157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo.
    Kozielski KL; Ruiz-Valls A; Tzeng SY; Guerrero-Cázares H; Rui Y; Li Y; Vaughan HJ; Gionet-Gonzales M; Vantucci C; Kim J; Schiapparelli P; Al-Kharboosh R; Quiñones-Hinojosa A; Green JJ
    Biomaterials; 2019 Jul; 209():79-87. PubMed ID: 31026613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
    Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
    Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3.
    Liang SF; Zuo FF; Yin BC; Ye BC
    Biomater Sci; 2022 Mar; 10(6):1582-1590. PubMed ID: 35179533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma.
    Hsieh HT; Huang HC; Chung CW; Chiang CC; Hsia T; Wu HF; Huang RL; Chiang CS; Wang J; Lu TT; Chen Y
    J Control Release; 2022 Dec; 352():920-930. PubMed ID: 36334859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single siRNA Nanocapsules for Effective siRNA Brain Delivery and Glioblastoma Treatment.
    Zou Y; Sun X; Wang Y; Yan C; Liu Y; Li J; Zhang D; Zheng M; Chung RS; Shi B
    Adv Mater; 2020 Jun; 32(24):e2000416. PubMed ID: 32374446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
    Zheng M; Liu Y; Wang Y; Zhang D; Zou Y; Ruan W; Yin J; Tao W; Park JB; Shi B
    Adv Mater; 2019 Sep; 31(37):e1903277. PubMed ID: 31348581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications.
    Huang C; Li M; Chen C; Yao Q
    Expert Opin Ther Targets; 2008 May; 12(5):637-45. PubMed ID: 18410245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
    Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
    Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma.
    Kievit FM; Wang K; Ozawa T; Tarudji AW; Silber JR; Holland EC; Ellenbogen RG; Zhang M
    Nanomedicine; 2017 Oct; 13(7):2131-2139. PubMed ID: 28614736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEI-Coated Fe₃O₄ Nanoparticles Enable Efficient Delivery of Therapeutic siRNA Targeting REST into Glioblastoma Cells.
    Wang R; Degirmenci V; Xin H; Li Y; Wang L; Chen J; Hu X; Zhang D
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness of Nanoparticles on Gene Therapy for Glioblastoma Cells Apoptosis: A Systematic Review.
    Alavian F; Ghasemi S
    Curr Gene Ther; 2021; 21(3):230-245. PubMed ID: 33655831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.
    Kane JR; Miska J; Young JS; Kanojia D; Kim JW; Lesniak MS
    Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii24-ii36. PubMed ID: 25746089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
    Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
    Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
    Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.